

1 A mathematical model for Zika virus
2 transmission with Optimal Control

3 Santosh Kumar Sharma ^{*1} and Nawin Jamar Agrawal²

4 ¹Department of Mathematics, K. L. S. College, Nawada, Magadh University, Bodh
5 Gaya, Bihar-805110, India

6 ²Department of Mathematics, L N Mithila University, Darbhanga Bihar 846008,
7 India

8 October 31, 2023

9 **Abstract**

10 In this research, we developed a mathematical model to study the co-
11 interaction of the Zika virus (a vector-borne disease). We qualitatively
12 analyzed the model and established the necessary conditions under which
13 disease-free and endemic equilibria are asymptotically stable. There are
14 only two possible equilibrium points in our system, two of which are en-
15 demic and one of which is devoid of disease. The disease-free equThe
16 most sensitive factors of the analyzed Zika model are the number of times
17 susceptible (infected) individuals were bitten by susceptible ilibrium is
18 shown by the theoretical study to be both locally and globally asymptot-
19 ically stable if the basic reproduction number is less than one. (infected)
20 mosquitoes, the host population's awareness rate, and the recovery rates
21 of susceptible (infected) humans. The World Health Organisation has
22 classified the current Zika virus (ZIKV) pandemic as a worldwide public
23 health emergency. Concerns include the lack of effective diagnostic tests
24 and vaccinations, the wide geographic range of mosquito species that can
25 spread the virus, and the lack of population immunity in recently impacted
26 nations.

27 **Keywords:** Zika virus, Reproduction number, Optimal control, Stability anal-
28 ysis, equilibrium point.

29 **1 Introduction**

30 Zika is a mosquito-borne virus that was initially discovered in a Rhesus macaque
31 monkey in Uganda in 1947. Infection and sickness in people were then discovered

*Corresponding author. Email: santoshmumath@gmail.com

32 in other African nations in the 1950s. Between the 1960s and the 1980s, isolated
33 cases of human infections were reported from Asia and Africa. However, since
34 2007, epidemics of the Zika virus infection have been documented in Africa,
35 the Americas, Asia, and the Pacific. When the Zika virus first emerged in the
36 Americas, a link between infection and microcephaly (a smaller-than-normal
37 head size) was first noticed.

38 The WHO declared a Public Health Emergency of International Concern
39 (PHEIC) in relation to microcephaly, other neurological disorders, and the Zika
40 virus as soon as the link between the Zika virus and congenital malformations
41 was confirmed. In India, Zika virus epidemic activity was discovered in 2021.
42 Although 89 nations and territories have yet to report evidence of Zika virus
43 infection brought on by mosquitoes, worldwide surveillance is still insufficient.
44 Symptoms of the Zika virus in most infected individuals are rare. If they develop,
45 they often begin 3–14 days after infection, are minor in nature, include rash,
46 fever, conjunctivitis, muscle and joint pain, malaise, and headache, and last
47 2–7 days on average. In tropical and subtropical areas, *Aedes* (*Stegomyia*)
48 genus mosquitoes, especially *Aedes aegypti*, are the major vectors of Zika virus
49 transmission.

50 In the course of the day, *Aedes* mosquitoes typically bite. Along with trans-
51 mitting urban yellow fever, these mosquitoes also spread dengue and chikun-
52 gunya. People who experience rashes, fevers, or joint discomfort should obtain
53 plenty of rest, drink lots of water, and use antipyretics and/or analgesics to
54 relieve their symptoms. Patients should seek medical attention and counseling
55 if their symptoms get worse. Pregnant women who live in Zika transmission
56 regions or who exhibit signs of the virus should consult a doctor for clinical
57 treatment, laboratory testing, education, and other services. Protection against
58 mosquito bites throughout the day and early evening is a vital step in avoiding
59 Zika virus infection, especially among pregnant women, women who are trying
60 to get pregnant, and young children. Examples of personal safety precautions
61 include dressing in clothing that covers as much of the body as possible and is
62 ideally light in color;

63 Recent studies, how the human and mosquito populations how the virus
64 spreads. The study by Ali et al [2], According to the studies by Gonzalez-Parra
65 Gilberto, et al [9], The Zika virus can be contained more effectively with the
66 help of educational programs and pesticide use. The study by Bernhauerov
67 et al [4], provided a numerical characterization of in vitro ZIKV infection and
68 contributed to a better understanding of the dynamics of ZIKV-host cell in-
69 teractions. A mathematical model and cost-effectiveness analysis to compare
70 different control strategies and emphasize the need for accurate implementation
71 of optimal control measures. by the studies, Wanget al. [18], In the study of
72 Aldila et al. [1], it was discovered that when R_0 is greater than 1, a local asymp-
73 tote, or endemic equilibrium point, exists. Reducing the impact of Zika on the
74 neighborhood may be possible with the addition of a class of asymptomatic car-
75 riers and the use of control measures. The studies of Khan et al. [11], According
76 to Bonyah et al. [6], studied the best strategies to control a co-infection model
77 while using the center manifold theory to examine the dynamics of a system.

78 Transmission dynamics between humans and mosquitoes, the impact of vaccina-
79 tion, and the effectiveness of different control strategies. In the study by Sharma
80 et al [16], The ideal control system employing prevention, treatment, and pesti-
81 cide spraying is determined by the stability analysis of the model's fixed points.
82 By the studies, Alzahrani et al [3], By the studies, Biswas et al. [5] provide cal-
83 culations and analysis to comprehend the dynamics of the virus in populations
84 of both humans and mosquitoes. Rezapour et al. [15] found that the fractional-
85 order Caputo derivative is what transmits the Zika virus between people and
86 mosquitoes. According to the study, Nwalozie et al. [13] better preventative,
87 control, and management measures are needed to decrease the consequences of
88 the Zika virus on world health. Studies by Mello et al. [7] show that baculovirus
89 expression technology is used in insect cell cultures to create vaccines against
90 arboviruses, such as ZIKV.

91 These techniques are being used by WHO to stop the Zika virus. who It
92 assists nations in confirming epidemics, offers technical assistance and direction
93 for the efficient control of disease outbreaks brought on by mosquitoes, looks into
94 the development of new tools, such as pesticide products and application tech-
95 nology, develops evidence-based strategies for managing attacks and solutions,
96 and assists nations in confirming epidemics with the assistance of its network of
97 cooperating laboratories.

98 Two areas where mathematical models have a big impact are the dynamics
99 of infectious diseases and the development of improved techniques to halt their
100 spread in the future. Using mathematical models, the dynamic is anticipated,
101 and this helps to create more efficient techniques for stopping its spread in the
102 future.

103 The numerical findings of our study were produced using built-in MATLAB
104 functions since we were more concerned with analyzing the qualitative dynam-
105 ical behaviors of the model under discussion than with the precision, rate of
106 convergence, etc. of the generated numerical solutions. Additionally, we have
107 created an optimum control issue for the system, where the objectives are to
108 reduce immunization and boost revenue.

109 In this study, we proposed epidemiological models for the Zika virus that
110 consider the virus' antigenic changes. In the models for transmission, specifics
111 on changes to the amino acid sequences of the HA proteins at epitope regions
112 were included. First, using the sequencing data, we calculated the rate of time-
113 varying antigenic change for each Zika virus subtype. Finally, we demonstrated
114 how changes in viral antigenicity may drastically influence the dynamics of Zika
115 virus transmission at the population level. In light of this, we suggested epi-
116 demiological models for the Zika viruses. We therefore proposed epidemiological
117 models for the Zika virus.

118 The article is organized as follows. In part 2, which is the section after this
119 one, we create the mathematical model. Fundamental characteristics like well-
120 posedness, nonnegativity, boundedness, etc. are examined in Section 3. Analysis
121 of equilibrium and stability is discussed in Section 4. Section 5 presents the topic
122 of best control. The discussion in Section 6 concludes the essay.




Figure 1: Schematic diagram of the model (1)

2 Formulation of Zika Virus Epidemic Model

The transmission model with media coverage is given by the following deterministic system of nonlinear ordinary differential equations

$$\begin{aligned}
 \frac{dS}{dt} &= \Lambda + \omega V - \frac{\beta SI}{1 + pI} - (\mu + \theta)S, \\
 \frac{dI}{dt} &= \frac{\beta SI}{1 + pI} + \frac{\beta' VI}{1 + pI} - (\mu + \alpha)I, \\
 \frac{dV}{dt} &= \theta S - (\mu + \omega)V - \frac{\beta' VI}{1 + pI}, \\
 \frac{dR}{dt} &= \alpha I - \mu R.
 \end{aligned} \tag{1}$$

where the initial conditions are

$$S = S_0, \quad I = I_0, \quad V = V_0, \quad R = R_0. \tag{2}$$

In this model, Λ is the constant production, ω is the ω , β is Transmission rate, p is Haf saturation constant, μ is Death rate, θ is Rate of vacillation, α is Rate of infected, and β' is Disseses transmission after vacillation. The schematic explanation of our proposed model is displayed in Figure 1. The values of the parameters of the model (1) are given in Table (1).

3 Stability of the equilibrium states

(A) The disease-free equilibrium of the system (1) is given by

$$E^0 = (S^0, I^0, V^0, R^0) = \left(\frac{\Lambda(\mu + \omega)}{\mu(\mu + \omega + \theta)}, 0, \frac{\Lambda\theta}{\mu(\mu + \omega + \theta)}, 0 \right). \tag{3}$$

134 (B) The endemic equilibrium of the system (1) is given by

$$E^* = (S^*, I^*, V^*, R^*),$$

135 It satisfies $S^* > 0$, $I^* > 0$, $V^* > 0$, $R^* > 0$ and

$$\begin{aligned} S^* &= \frac{Y_1 - (\Lambda + \omega V^*)}{(\mu + \theta)}, \\ I^* &= \frac{(Y_1 + Y_2)}{(\mu + \alpha)}, \\ V^* &= \frac{(\theta S^* - Y_2)}{(\mu + \alpha)}, \\ R^* &= \frac{\alpha I^*}{\mu}. \end{aligned} \tag{4}$$

136 where,

$$Y_1 = \frac{\beta S^* I^*}{(1 + pI^*)} \text{ and } Y_2 = \frac{\beta' V^* I^*}{(1 + pI^*)}.$$

137 Substituting the above into the second equation at equilibrium will yield the
138 expression for I after some rearrangement. For illustration,

139 4 Basic reproduction number of the model

140 The local stability of the system E^0 is governed by the basic reproduction num-
141 ber $R_0 < 1$. The basic reproduction number is the average number of new
142 secondary infections in entirely susceptible Zika virus produced by a single in-
143 fected Zika virus. With the help of the next generation method [17], we can
144 calculate the basic reproduction number. For this method, we consider the
145 model variables in such a manner that the compartments reflect only infected
146 individuals. By this assumption, we have $y = (S, I, V, R)$, where I are the
147 infected compartments. Furthermore, \mathcal{G}_H denotes the set of all infection-free
148 states—that is,

$$\mathcal{X}_H = \{X \geq 0 : X_i, i = 1, 2\}. \tag{5}$$

149 System (1) is rewritten as

$$X'_i = h_i(X) = \mathcal{F}_i(X) - \mathcal{G}_i(X), \quad i = 1, 2, \tag{6}$$

150 where $\mathcal{F}_i(X)$ describes the rate of appearance of new infections in compartment
151 i . Moreover,

$$\mathcal{Y}_i(X) = \mathcal{G}_i^-(X) - \mathcal{G}_i^+(X), \tag{7}$$

152 $\mathcal{Y}_i^+(X)$ is the transmission rate into the compartment i , and $\mathcal{Y}_i^-(X)$ is the
153 rate of transmission out of this compartment. The subsequent norms are to be
154 modeled.

155 (B₁) $\mathcal{F}_i(X) \geq 0$, $\mathcal{G}_i^-(X) \geq 0$, $\mathcal{G}_i^+(X) \geq 0$, for any $X \geq 0$;

156

157 (B₂) If $X_i = 0$, then $\mathcal{G}_i^- = 0$;

158

159 (B₃) $\mathcal{F}_i = 0$, for $i = 2$;

160

161 (B₄) If $X \in \mathcal{X}_H$, then $\mathcal{F}_i(X) = 0$, $\mathcal{G}_i^+(X) = 0$, for $i = 1, 2$;

162

163 (B₅) For the disease-free equilibrium (DFE) X_0 , the Jacobi matrix $Dh(X_0)$
164 constrained to the subspace $h = 0$ has all negative eigenvalues.

165 To formulate the next generation matrix FG^{-1} [17] from matrices of partial
166 derivatives of \mathcal{F}_i and \mathcal{G}_i . Specifically,

$$F = \left[\frac{\partial \mathcal{F}_i(X_0)}{\partial X_j} \right], \quad G = \left[\frac{\partial \mathcal{G}_i(X_0)}{\partial X_j} \right], \quad (8)$$

167 where $i, j = 1, 2$. Here, F, G are two-dimensional squared matrices and $R_0 =$
168 $\varrho(FG^{-1})$ (ϱ denotes a spectral radius of the matrix). For model (1), we have

$$\mathcal{F} = \begin{pmatrix} \frac{\beta SI}{1+pI} + \frac{\beta' VI}{(1+pI)} & 0 \\ 0 & 0 \end{pmatrix}, \quad \mathcal{G} = \begin{pmatrix} (\mu + \alpha)I & 0 \\ -\alpha I + \mu R & \mu \end{pmatrix}. \quad (9)$$

169 Next, we are setting that the entry-wise non-negative new infection matrix
170 is F . Let the non-singular Metzler matrix [12] define the transitions of Zika
171 virus infection between the infection compartments and the matrices, which are
172 given as follows.

$$F = \begin{pmatrix} \frac{\beta S}{(1+pI)^2} + \frac{\beta' V}{(1+pI)^2} & 0 \\ 0 & 0 \end{pmatrix}, \quad G = \begin{pmatrix} \mu + \alpha & 0 \\ -\alpha & \mu \end{pmatrix},$$

$$G^{-1} = \begin{pmatrix} \frac{1}{(\mu + \alpha)} & 0 \\ \frac{\alpha}{\mu(\mu + \alpha)} & \frac{1}{\mu} \end{pmatrix}.$$

173 We observe that G^{-1} is also an entry-wise non-negative matrix and thus
174 FG^{-1} is an entry-wise non-negative next-generation matrix showing the ex-
175 pected number of new infections which is given by

$$\begin{aligned} FG^{-1} &= \begin{bmatrix} \frac{\beta S}{(1+pI)^2} + \frac{\beta' V}{(1+pI)^2} & 0 \\ 0 & 0 \end{bmatrix} \times \begin{bmatrix} \frac{1}{(\mu + \alpha)} & 0 \\ \frac{\alpha}{\mu(\mu + \alpha)} & \frac{1}{\mu} \end{bmatrix}, \\ &= \begin{bmatrix} \frac{\beta S + \beta' V}{(1+pI)^2(\mu + \alpha)} & 0 \\ 0 & 0 \end{bmatrix}. \end{aligned} \quad (10)$$

Table 1: Parameters and their associated sensitivity indices along with the relative percentage impact on the threshold quantity (R_0)

Parameter	Definition	Value	Reference
Λ	Birth rate		
ω			
β	Transmission rate		
p	Haf saturation costant		
μ	Death rate		
θ	Rate of vacillation		
α	Rate of infected		
β'	Disseses transmission after vacillation		

176 Using the spectral radius of the next-generation matrix [10, 17], for the sys-
 177 tem (1), we find the basic reproduction number R_0 , which is the largest eigen-
 178 value of FG^{-1} at E^0 . Thus,

$$\begin{aligned} \mathcal{R}_0 &= \frac{\beta S + \beta' V}{(\mu + \alpha)}, \\ &= \frac{\beta S \mu (\mu + \omega + \theta) + \beta' \Lambda \theta}{\mu (\mu + \alpha) (\mu + \omega + \theta)}. \end{aligned} \quad (11)$$

179 **Theorem 1.** *The system (1) describes the spreading kinetics of Zika virus*
 180 *infection, which has a threshold parameter basic reproduction number $R_0 =$*
 181 *$\frac{\beta S \mu (\mu + \omega + \theta) + \beta' \Lambda \theta}{\mu (\mu + \alpha) (\mu + \omega + \theta)}$ at E^0 . For $R_0 > 1$, the system (1) has a unique positive*
 182 *endemic steady state.*

183 5 Local stability of the disease-free equilibrium

184 **Theorem 2.** *The disease-free equilibrium E^0 is locally asymptotically stable if*
 185 *$R_0 < 1$, and unstable if $R_0 > 1$.*

186 *Proof.* The Jacobian of the system (1) evaluated at E^0 is given by

$$J_{E^0} = \begin{pmatrix} -(\mu + \theta) & -\beta S & \omega & 0 \\ 0 & \beta S + \beta' V - (\mu + \alpha) & 0 & 0 \\ \theta & -\beta' V & -(\mu + \omega) & 0 \\ 0 & \alpha & 0 & -\mu \end{pmatrix}. \quad (12)$$

187 Here the eigenvalues are $[\lambda = -\mu, \{(\beta S + \beta' V) - (\mu + \alpha)\}]$ and the other
 188 two eigenvalues are determined from the given equation

$$\begin{vmatrix} -(\mu + \theta) - \lambda & \omega \\ \theta & -(\mu + \omega) - \lambda \end{vmatrix} = 0 \quad (13)$$

189 and the characteristic equation for (13) is

$$A_0\lambda^2 + A_1\lambda + A_2\lambda = 0. \quad (14)$$

190 where,

$$A_0 = 1 > 0, \quad A_1 = (\omega + \theta + 2\mu), \quad A_2 = (\mu^2 + \mu\theta + \mu\omega).$$

191 Now, it is easy to note that $A_0 \geq 0$, and $A_1 > 0$. If $A_0 > 0$, then all the
 192 roots of Equation (4) will be negative (Section 3.3 in [10]). If $A_2 > 0$, then we
 193 have threshold criteria to determine the stability condition at the infection-free
 194 point E^0 . We have the condition $\mu_1 + 2\frac{p\hat{H}_S}{H_T} < \nu < \frac{\mu_2\mu_3}{\beta_1\hat{H}_S}$, which implies that
 195 $R_0 < 1$ and results in the eradication of infection. \square

196 5.1 Local stability of the endemic equilibrium:

197 **Theorem 3.** *The system (1) around E^* is locally asymptotically stable (LAS)*
 198 *if $R_0 > 1$.*

199 *Proof.* We already established that the equilibrium E^* is feasible when $R_0 > 1$.
 200 Now, the Jacobi matrix around E^* is

$$|J_{E^*} - \lambda| = \begin{pmatrix} a_{11} - \lambda & a_{12} & a_{13} & 0 \\ a_{21} & a_{22} - \lambda & 0 & 0 \\ a_{31} & a_{32} & a_{33} - \lambda & 0 \\ 0 & a_{42} & 0 & a_{44} - \lambda \end{pmatrix}. \quad (15)$$

201 where,

$$\begin{aligned} a_{11} &= -\frac{\beta I}{(1+pI)} - (\mu + \theta), & a_{12} &= -\frac{\beta S}{(1+pI)^2}, \\ a_{21} &= \frac{\beta I}{(1+pI)}, & a_{22} &= \frac{\beta S + \beta'V}{(1+pI)^2} - (\mu + \alpha), \\ a_{32} &= -\frac{\beta'V}{(1+pI)^2}, & a_{33} &= -(\mu + \omega) - \frac{\beta' I}{(1+pI)}, \\ a_{13} &= \omega, & a_{31} &= \theta, & a_{42} &= \alpha, & a_{44} &= \mu. \end{aligned}$$

202 At E^* , the characteristic equation is

$$\lambda^4 - x_1\lambda^3 + x_2\lambda^2 + x_3\lambda + x_4\lambda^0 = 0. \quad (16)$$

203 where,

$$\begin{aligned} x_1 &= (a_{33} + a_{44} + a_{11} + a_{22}), \\ x_2 &= (a_{33}a_{44} + a_{11}a_{33} + a_{22}a_{44} + a_{11}a_{22}), \\ x_3 &= (a_{33}a_{44} - a_{11}a_{22}a_{33} - a_{11}a_{22}a_{44}), \\ x_4 &= (a_{11}a_{22}a_{33}a_{44}). \end{aligned}$$

204 By the Routh-Hurwitz criteria at the endemic equilibrium E^* , the system (1)
 205 is LAS if $R_0 > 1$. \square

206 **6 Global Stability**

207 **Theorem 4.** *The system is globally asymptotically stable (GAS) when $R_0 < 0$.*

208 *Proof.* We consider the Lyapunov function as follows:

$$L_1 = \xi_1 I + \xi_2 V + \xi_3 R. \quad (17)$$

209 Differentiating the Lyapunov function $L_1(17)$ with respect to t , we find

$$\begin{aligned} \frac{dL_1}{dt} &= \xi_1 \frac{dI}{dt} + \xi_2 \frac{dR}{dt} \\ &= \xi_1 \left[\frac{\beta SI}{(1+pI)} + \frac{\beta' VI}{(1+pI)} - (\mu + \alpha)I \right] + \xi_2(\alpha I - \mu R) \end{aligned} \quad (18)$$

210 When $R_0 < 1$, we have $\frac{dL_1}{dt} < 0$ and $\frac{dL_1}{dt} = 0$ implies that $R = 0$. From the
211 model (1), we can say that $I = 0$ when $R = 0$ in the limit $t \rightarrow 0$. Hence, ac-
212 cording to the Lyapunov–LaSalle theorem, the system is globally asymptotically
213 stable when $R_0 < 1$. This completes the proof. \square

214 **Theorem 5.** *The endemic equilibrium E^* is globally asymptotically stable (GAS)*
215 *if $R_0 > 1$.*

216 *Proof.* Let us consider the Dulac function:

$$D(S, I, V, R) = \frac{1}{(S I V R)}, \quad (19)$$

217 and denote the R.H.S of equations in the system (1) as

$$\begin{aligned} Z_1 &= \Lambda + \omega V - \frac{\beta SI}{1+pI} - (\mu + \theta)S, \\ Z_2 &= \frac{\beta SI}{1+pI} + \frac{\beta' VI}{1+pI} - (\mu + \alpha)I, \\ Z_3 &= \theta S - (\mu + \omega)V - \frac{\beta' VI}{1+pI}, \\ Z_4 &= \alpha I - \mu R. \end{aligned} \quad (20)$$

218 Then, from (20), we have

$$\begin{aligned} \frac{\partial(DZ_1)}{\partial S} &= -\frac{1}{S^2 I V R} \left[\Lambda + \omega V - \frac{\beta SI}{(1+pI)} - (\mu + \theta)S \right] \\ &\quad + \frac{1}{S I V R} \left[-\frac{\beta I}{(1+pI)} - (\mu + \theta) \right], \\ &= -\frac{(\Lambda + \omega V)}{S^2 I V R} < 0, \end{aligned} \quad (21)$$

$$\begin{aligned}
\frac{\partial(DZ_2)}{\partial I} &= -\frac{1}{SI^2VR} \left[\frac{\beta SI + \beta' VI}{(1+pI)} - (\mu + \alpha)I \right] \\
&\quad + \frac{1}{SIVR} \left[\frac{\beta S + \beta' V}{(1+pI)^2} - (\mu + \alpha) \right], \\
&\quad - \frac{p(\beta S + \beta' V)}{SVR(1+pI)^2} < 0,
\end{aligned} \tag{22}$$

$$\begin{aligned}
\frac{\partial(DZ_3)}{\partial I} &= -\frac{1}{SIV^2R} \left[\theta S - (\mu + \omega)V - \frac{\beta' VI}{(1+pI)} \right] \\
&\quad + \frac{1}{SIVR} \left[-(\mu + \omega) - \frac{\beta' I}{(1+pI)} \right], \\
&\quad - \frac{\theta S}{SIV^2R} < 0,
\end{aligned} \tag{23}$$

$$\begin{aligned}
\frac{\partial(DZ_4)}{\partial I} &= -\frac{1}{SIVR^2}(\alpha I - \mu R) + \frac{1}{SIVR}(-\mu), \\
&\quad - \frac{\alpha I}{SIVR^2} < 0.
\end{aligned} \tag{24}$$

219 From the inequalities (21)-(24), we find

$$\frac{\partial(DZ_1)}{\partial S} + \frac{\partial(DZ_2)}{\partial I} + \frac{\partial(DZ_3)}{\partial V} + \frac{\partial(DZ_4)}{\partial R} < 0. \tag{25}$$

220 Thus, every positive solution of the system (1) tends to the endemic equilibrium
221 E^* when $R_0 > 1$. According to the Dulac–Bendixson theorem, there exists no
222 periodic orbit for (1), and hence the system is globally asymptotically stable for
223 E^* . \square

224 7 The optimal control model

225 Control theoretic study plays a pivotal role in the minimization of different in-
226 fectious diseases. We use optimization techniques to develop an optimal control
227 mechanism that minimizes the transmission of the novel Zika virus. We have in-
228 corporated the combination of two control parameters/variables as symbolized
229 by $u(t)$ and define it as $u(t) = \{u_1(t), u_2(t)\}$. Physically or biologically these
230 control measures represent the reverse transcript inhibitor, and the control min-
231 imizing the reservoir contribution to the virus. We place the control functions

232 into the model (1) which leads to the following state system:

$$\begin{aligned}
\frac{dS}{dt} &= \Lambda + \omega V - \frac{\beta SI}{\{1 + (1 - u_2)pI\}} - \{\mu + (1 - u_1)\theta\}S, \\
\frac{dI}{dt} &= \frac{\beta SI}{\{1 + (1 - u_2)pI\}} + \frac{\beta' VI}{\{1 + (1 - u_2)pI\}} - (\mu + \alpha)I, \\
\frac{dV}{dt} &= (1 - u_1)\theta S - (\mu + \omega)V - \frac{\beta' VI}{\{1 + (1 - u_2)pI\}}, \\
\frac{dR}{dt} &= \alpha I - \mu R.
\end{aligned} \tag{26}$$

233 where the initial conditions are

$$S = S_0, \quad I = I_0, \quad V = V_0, \quad R = R_0. \tag{27}$$

234 We define the objective cost function as follows:

$$J[u, x] = \int_0^{t_f} (Au_1^2 + Bu_2^2 + CI^2)dt \tag{28}$$

235 Here the main aim is to minimize the cost function subject to the state system
236 (26).

237 In the objective function described by (28), where $x = (S, I, V, R)$ and
238 A, B and C, are the positive constants called weight constants. The weight-
239 ing constants I are the relative costs of infection and virus, while A and B are
240 the weighting constants that measure the associated cost of the control variables
241 $u_1(t)$ and $u_2(t)$ respectively.

242 We have to find the optimal control function represented by (u_1^*, u_2^*) such
243 that

$$J(u_1^*, u_2^*) = \min\{J(u_1, u_2), u_i \in \mathcal{U}, \text{ for } i = 1, 2\}, \tag{29}$$

244 subject to the state system (26) and the control set \mathcal{U} is described as:

$$\mathcal{U} = \{(u_1, u_2,) : u_i \text{ is Lebesgue measurable and } 0 \leq u_i(t) \leq 1, i = 1, 2\}. \tag{30}$$

245 where \mathcal{U} is the control set. The basic concept of an optimal control problem
246 is to prove the existence of optimal control through an optimality system [14].
247 Here we prove the existence condition of optimal control problem by using the
248 approach of Fleming and Rishel [8].

249 Further to proceed, the existence of such control measures variables will be
250 shown. The existence of a system is subjected to the boundedness of the controls
251 as well as Lebesgue measurable, and the initial data non-negativity. Thus the
252 control problem may take the form:

$$\frac{dX}{dt} = PX + Q(X). \tag{31}$$

253 where $X = (S, I, V, R)'$, and the matrices P and $Q(X)$ respectively containing
254 the linear and nonlinear bounded coefficients are given by the following:

255 **Theorem 6.** *There exists an optimal solution $u^* = (u_1^*, u_2^*) \in \mathcal{U}$ to the control*
 256 *problem (42).*

257 *Proof.* Clearly, the state and control variables have non-negative values. Fur-
 258 thermore, the set of control \mathcal{U} is closed and convex. Moreover, the boundedness
 259 of the control system leads to its compactness. The integral functional (28) is
 260 also convex. Therefore, optimal controls exist. \square

261 7.1 Methodology

262 Let the control input $u^*(t)$ denote the quantity of the drug dose at time t . The
 263 cost function (28) subject to the system of ODE (26) represents the necessary
 264 conditions for which an optimal control and corresponding states must sat-
 265 isfy Pontryagin's Maximum Principle. To determine the optimal control $u_1^*(t)$
 266 and $u_2^*(t)$, we use Pontryagin's maximum principle [14]. With the aid of this
 267 principle, we change the system (42) and the cost function (28) into a mini-
 268 mizing problem by constructing the Hamiltonian function H with respect to
 269 $(u_1(t), u_2(t))$.

270 We find the optimal values to the problem described by (28) subject to
 271 the control system (26). For that, the Lagrangian, as well as the Hamiltonian
 272 associated with the control problem, will be defined. Therefore, we take the
 273 state variable x and control variable u to define the Lagrangian (\mathcal{L}) as

$$\mathcal{L} = Au_1^2 + Bu_2^2 + CI. \quad (32)$$

274 Using the adjoint variables together with the state variables, the Hamiltonian
 275 is constructed as follows:

$$\begin{aligned} \mathcal{H} = & Au_1^2 + Bu_2^2 + CI^2 \\ & + \lambda_1 \left[\Lambda + \omega V - \frac{\beta SI}{\{1 + (1 - u_2)pI\}} - \{\mu + (1 - u_1)\theta\}S \right] \\ & + \lambda_2 \left[\frac{\beta SI}{\{1 + (1 - u_2)pI\}} + \frac{\beta' VI}{\{1 + (1 - u_2)pI\}} - (\mu + \alpha)I \right] \\ & + \lambda_3 \left[(1 - u_1)\theta S - (\mu + \omega)V - \frac{\beta' VI}{\{1 + (1 - u_2)pI\}} \right] \\ & + \lambda_4(\alpha I - \mu R). \end{aligned} \quad (33)$$

276 Here, ξ_i , $i = 1, 2, 3, 4$ denote the adjoint variables, P and Q are the weight
 277 constants, and A represents the penalty multiplier.

278 From (33), we have

$$\begin{aligned}
\frac{\partial \mathcal{H}}{\partial S} &= \frac{\beta I}{\{1 + (1 - u_2)pI\}}(\lambda_2 - \lambda_1) - \lambda_1\{\mu + (1 - u_1)\theta\} + \lambda_3(1 - u_1)\theta, \\
\frac{\partial \mathcal{H}}{\partial I} &= 2CI + \frac{\beta S}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_1) + \frac{\beta' V}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_3) - \lambda_2(\mu + \alpha) + \lambda_4(\alpha), \\
\frac{\partial \mathcal{H}}{\partial V} &= \lambda_1\omega + \frac{\beta' I}{\{1 + (1 - u_2)pI\}}(\lambda_2 - \lambda_3) - \lambda_3(\mu + \omega), \\
\frac{\partial \mathcal{H}}{\partial R} &= \lambda_4(-\mu), \\
\frac{\partial \mathcal{H}}{\partial u_1} &= 2Au_1 + \theta S(\lambda_1 - \lambda_3), \\
\frac{\partial \mathcal{H}}{\partial u_2} &= 2Bu_2 + \frac{\beta SpI^2}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_1) + \frac{\beta' VpI^2}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_3).
\end{aligned} \tag{34}$$

279 According to Pontryagin's minimum principle, the adjoint variables satisfy,

$$\frac{d\xi}{dt} = -\frac{\partial \mathcal{H}}{\partial x}. \tag{35}$$

280 Therefore, using (35), the adjoint system evaluated at optimal controls input
281 $(u_1(t), u_2(t))$ and corresponding to the model state variables (S, I, V, R) is ob-
282 tained as:

$$\begin{aligned}
\frac{d\lambda_1}{dt} &= -\left[\frac{\beta I}{\{1 + (1 - u_2)pI\}}(\lambda_2 - \lambda_1) - \lambda_1\{\mu + (1 - u_1)\theta\} + \lambda_3(1 - u_1)\theta \right], \\
\frac{d\lambda_2}{dt} &= -\left[2CI + \frac{\beta S}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_1) + \frac{\beta' V}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_3) - \lambda_2(\mu + \alpha) + \lambda_4(\alpha) \right], \\
\frac{d\lambda_3}{dt} &= -\left[\lambda_1\omega + \frac{\beta' I}{\{1 + (1 - u_2)pI\}}(\lambda_2 - \lambda_3) - \lambda_3(\mu + \omega) \right], \\
\frac{d\lambda_4}{dt} &= -[\lambda_4(-\mu)].
\end{aligned} \tag{36}$$

283 The transversality conditions are $\lambda_1(t_f) = 0$, $\lambda_2(t_f) = 0$, $\lambda_3(t_f) = 0$, $\lambda_4(t_f) =$
284 0 . Now Pontryagin's Maximum Principle [14] states that the unconstrained op-
285 timal control $u^*(t)$ satisfies

$$\frac{\partial H}{\partial u(t)} = 0. \tag{37}$$

286 This gives,

$$\begin{aligned}
\frac{\partial \mathcal{H}}{\partial u_1} &= 2Au_1 + \theta S(\lambda_1 - \lambda_3) = 0, \\
\frac{\partial \mathcal{H}}{\partial u_2} &= 2Bu_2 + \frac{\beta SpI^2}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_1) \\
&\quad + \frac{\beta' VpI^2}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_3) = 0.
\end{aligned} \tag{38}$$

287 Solving (38) these for optimal control, we obtain

$$\begin{aligned}
u_1^*(t) &= \frac{(\lambda_3 - \lambda_1)\theta S}{2A}, \\
u_2^*(t) &= \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B},
\end{aligned} \tag{39}$$

288 where,

$$K = \frac{\beta SpI^2}{\{1 + (1 - u_2)pI\}^2}, \quad K' = \frac{\beta' VpI^2}{\{1 + (1 - u_2)pI\}^2}.$$

289 Since the standard control is bounded, we conclude for the control $u_1(t)$, $u_2(t)$:

$$u_1^*(t) = \begin{cases} 0, & \frac{(\lambda_3 - \lambda_1)\theta S}{2A} < 0, \\ \frac{(\lambda_3 - \lambda_1)\theta S}{2A}, & 0 < \frac{(\lambda_3 - \lambda_1)\theta S}{2A} < 1, \\ 1, & \frac{(\lambda_3 - \lambda_1)\theta S}{2A} > 1. \end{cases} \tag{40}$$

$$u_2^*(t) = \begin{cases} 0, & \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B} < 0, \\ \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B}, & 0 < \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B} < 1, \\ 1, & \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B} > 1. \end{cases} \tag{41}$$

290 Hence the compact form of $u_1^*(t)$ is

$$u_1^*(t) = \max \left(\min \left(1, \frac{(\lambda_3 - \lambda_1)\theta S}{2A} \right), 0 \right).$$

291 Similarly, we can obtain the compact form of $u_2^*(t)$ in the form of.

$$u_2^*(t) = \max \left(\min \left(1, \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B} \right), 0 \right).$$

292 Utilizing the equation and taking the state system along with the adjoint system,
293 and the transversality conditions, we have the following optimal system:

$$\begin{aligned}
\frac{dS}{dt} &= \Lambda + \omega V - \frac{\beta SI}{\{1 + (1 - u_2)pI\}} - \{\mu + (1 - u_1)\theta\}S, \\
\frac{dI}{dt} &= \frac{\beta SI}{\{1 + (1 - u_2)pI\}} + \frac{\beta'VI}{\{1 + (1 - u_2)pI\}} - (\mu + \alpha)I, \\
\frac{dV}{dt} &= (1 - u_1)\theta S - (\mu + \omega)V - \frac{\beta'VI}{\{1 + (1 - u_2)pI\}}, \\
\frac{dR}{dt} &= \alpha I - \mu R, \\
\frac{d\lambda_1}{dt} &= - \left[\frac{\beta I}{\{1 + (1 - u_2)pI\}}(\lambda_2 - \lambda_1) - \lambda_1\{\mu + (1 - u_1)\theta\} + \lambda_3(1 - u_1)\theta \right], \\
\frac{d\lambda_2}{dt} &= - \left[2CI + \frac{\beta S}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_1) + \frac{\beta'V}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_3) - \lambda_2(\mu + \alpha) + \lambda_4(\alpha) \right], \\
\frac{d\lambda_3}{dt} &= - \left[\lambda_1\omega + \frac{\beta' I}{\{1 + (1 - u_2)pI\}}(\lambda_2 - \lambda_3) - \lambda_3(\mu + \omega) \right], \\
\frac{d\lambda_4}{dt} &= - [\lambda_4(-\mu)].
\end{aligned} \tag{42}$$

294 with the initial conditions as: $S(0) > 0$, $I(0) > 0$, $V(0) > 0$, $R(0) > 0$. and
295 boundary conditions as: $\lambda_i(t_f) = 0$, $i = 1, 2, 3, 4$.

296 8 Conclusion

297 In this study, we focused on the role during Zika-virus-Infection in our inves-
298 tigation. Furthermore, a deterministic SEIVR Zika epidemic model is created,
299 investigated, and analysed, utilising nonlinear stability and optimal control the-
300 ory. Hier, the proposed model's positivity and boundedness are examined. Using
301 a next-generation matrix approach, we were able to determine the fundamental
302 reproduction number. The steady-state analysis demonstrates that, if the ba-
303 sic reproduction number R'_o is smaller than unity, the disease-free equilibrium
304 (DFE) ist globally asymptotically stable. Endemic equilibrium is locally asymp-
305 totically stable, if the fundamental reproduction number R'_o is bigger than 1.
306 It is a requirement that the reproduction number be fewer than one, in order
307 to eradicate the zikavirus from the populace. Of course, we cannot take into
308 account all such considerations in order to avoid complexity. However, we plan
309 to consider these options in our future work.

310 References

- 311 [1] D Aldila, K Rasyiqah, G Ardaneswari, and H Tasman. A mathematical
312 model of zika disease by considering transition from the asymptomatic to
313 symptomatic phase. In *Journal of Physics: Conference Series*, volume
314 1821, page 012001. IOP Publishing, 2021.

- 315 [2] Aatif Ali, Saeed Islam, M Riaz Khan, Saim Rasheed, FM Allehiany, Jamel
316 Baili, Muhammad Altaf Khan, and Hijaz Ahmad. Dynamics of a frac-
317 tional order zika virus model with mutant. *Alexandria Engineering Journal*,
318 61(6):4821–4836, 2022.
- 319 [3] Ebraheem O Alzahrani, Wisal Ahmad, Muhammad Altaf Khan, and
320 Sharaf J Malebary. Optimal control strategies of zika virus model with
321 mutant. *Communications in Nonlinear Science and Numerical Simulation*,
322 93:105532, 2021.
- 323 [4] Veronika Bernhauerová, Veronica V Rezelj, and Marco Vignuzzi. Modelling
324 degradation and replication kinetics of the zika virus in vitro infection.
325 *Viruses*, 12(5):547, 2020.
- 326 [5] Sudhanshu Kumar Biswas, Uttam Ghosh, and Susmita Sarkar. Mathe-
327 matical model of zika virus dynamics with vector control and sensitivity
328 analysis. *Infectious Disease Modelling*, 5:23–41, 2020.
- 329 [6] Ebenezer Bonyah, Muhammad Altaf Khan, Kazeem Oare Okosun, and
330 JF Gómez-Aguilar. On the co-infection of dengue fever and zika virus.
331 *Optimal Control Applications and Methods*, 40(3):394–421, 2019.
- 332 [7] Renata Gois de Mello, Thaissa Consoni Bernardino, Luis Giovanni Oliveira
333 Guardalini, Renato Mancini Astray, Marta Maria Antoniazzi, Simone
334 Gonçalves Silva Jared, Eutimio Gustavo Fernández Núñez, and Soraia At-
335 tie Calil Jorge. Zika virus-like particles (vlps) produced in insect cells.
336 *Frontiers in Pharmacology*, 14:1181566, 2023.
- 337 [8] Wendell H Fleming and Raymond W Rishel. *Deterministic and stochastic*
338 *optimal control*, volume 1. Springer Science & Business Media, 2012.
- 339 [9] Gilberto González-Parra, Miguel Díaz-Rodríguez, and Abraham J Arenas.
340 Optimization of the controls against the spread of zika virus in populations.
341 *Computation*, 8(3):76, 2020.
- 342 [10] Jane M Heffernan, Robert J Smith, and Lindi M Wahl. Perspectives on the
343 basic reproductive ratio. *Journal of the Royal Society Interface*, 2(4):281–
344 293, 2005.
- 345 [11] MA Khan, Syed Wasim Shah, Saif Ullah, and JF Gómez-Aguilar. A dy-
346 namical model of asymptomatic carrier zika virus with optimal control
347 strategies. *Nonlinear Analysis: Real World Applications*, 50:144–170, 2019.
- 348 [12] Kumpati S Narendra and Robert Shorten. Hurwitz stability of metzler ma-
349 trices. *IEEE Transactions on Automatic Control*, 55(6):1484–1487, 2010.
- 350 [13] Rhoda Nwalozie, Roseanne Adah Ikpeama, Brenda Anyakwe Nnokam, and
351 Rose Mary Kaiso Esiere. A review on zika virus: Epidemiology, patho-
352 genesis and clinical outcomes. *International Journal of Pathogen Research*,
353 12(3):35–41, 2023.

- 354 [14] Lev Semenovich Pontryagin. *Mathematical theory of optimal processes*.
355 CRC press, 1987.
- 356 [15] Shahram Rezapour, Hakimeh Mohammadi, and Amin Jajarmi. A new
357 mathematical model for zika virus transmission. *Advances in difference*
358 *equations*, 2020(1):1–15, 2020.
- 359 [16] Naveen Sharma, Ram Singh, Jagdev Singh, and Oscar Castillo. Modeling
360 assumptions, optimal control strategies and mitigation through vaccination
361 to zika virus. *Chaos, Solitons & Fractals*, 150:111137, 2021.
- 362 [17] Pauline Van den Driessche and James Watmough. Reproduction numbers
363 and sub-threshold endemic equilibria for compartmental models of disease
364 transmission. *Mathematical biosciences*, 180(1-2):29–48, 2002.
- 365 [18] Xia Wang, Mingwang Shen, Yanni Xiao, and Libin Rong. Optimal control
366 and cost-effectiveness analysis of a zika virus infection model with compre-
367 hensive interventions. *Applied Mathematics and Computation*, 359:165–185,
368 2019.